Azitra, Inc.

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “anticipates,” “believes,” “could,” “expects,” “intends,” “may,” “plans,” “potential,” “will,” “foreseeable future,” and variations of these words or similar expressions. Any statements in this Current Report on Form 8-K that are not statements of historical fact may be deemed forward-looking statements. These include, without limitation, statements about the Company’s intentions regarding the ATM Program; the Company’s future financing activities and capital resources; the expected timing of the Company’s initiation, enrollment and provision of data and results for its ATR-COSF program; and the Company’s anticipated trials, clinical and preclinical programs, including ATR-COSF, and its corporate and clinical/preclinical strategies, including its cosmeceutical strategy. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the resumption of sales under the ATM Program or pursuit of other financing activities; holders of warrants may not exercise them; possible delays in the initiation and enrollment of, and the provision of data and results from the Company’s ATR-COSF human trial and data; the Company’s need for additional capital to fund its operations and clinical programs, market conditions, and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this report, and the Company undertakes no obligation to update them except as required by law.